FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993726573> ?p ?o ?g. }

• W1993726573 endingPage "155" @default.
• W1993726573 startingPage "150" @default.
• W1993726573 abstract "ObjectivesThe purpose of this study was to document the results of bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations (LMs), and the clinical data of 65 patients between October 2004 and October 2007 were reviewed.MethodsOf the 65 patients in the study, 60 patients were given intralesional injection of bleomycin A5. Five patients underwent partial resection, and then an injection of bleomycin A5 for the remaining lesion. The outcomes were assessed by physical examination and Doppler ultrasonography scan. The follow-up time was from 6 months to 3 years after the last injection (mean, 16 months).ResultsAmong the 65 patients, 41 were men and 24 were women (1.7:1 male:female ratio), the age range was 3 months to 45 years (mean, 12 years). Thirty-two lesions (49%) were macrocystic, 30 (46%) were microcystic, and 3 (5%) were combined. Each patient received 1 to 10 injections (mean, 3.0 injections) for the whole course of treatment, and the total dose of bleomycin A5 was from 8 to 80 milligrams (mean, 24.0 mg). Twenty-six of 32 macrocystic lesions (81%) showed greater than 90% reduction, whereas another 6 (19%) exhibited 50% to 90% reduction. Nineteen of 30 microcystic lesions (63%) showed greater than 90% reduction; 10 (33%) had 50% to 90% reduction; and 1 (4%) had less than 50% size reduction. Of the 3 combined lesions, 2 (67%) had greater than 90% shrinkage, and 1 (3%) had less than 50% reduction. The complications included ulceration of oral mucosa, minor soft tissue atrophy, mild fever, and hematoma. There was no recurrence throughout the follow-up period.ConclusionThese data suggest bleomycin A5 is a safe and effective intralesional agent for the treatment of macrocystic LMs, superficial oral mucosa LM, and localized deep microcystic lesions. For extensive macrocystic LMs involving contiguous anatomic areas and diffuse microcystic lesions involving deep tissues, bleomycin A5 injection combined with resection is necessary. The purpose of this study was to document the results of bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations (LMs), and the clinical data of 65 patients between October 2004 and October 2007 were reviewed. Of the 65 patients in the study, 60 patients were given intralesional injection of bleomycin A5. Five patients underwent partial resection, and then an injection of bleomycin A5 for the remaining lesion. The outcomes were assessed by physical examination and Doppler ultrasonography scan. The follow-up time was from 6 months to 3 years after the last injection (mean, 16 months). Among the 65 patients, 41 were men and 24 were women (1.7:1 male:female ratio), the age range was 3 months to 45 years (mean, 12 years). Thirty-two lesions (49%) were macrocystic, 30 (46%) were microcystic, and 3 (5%) were combined. Each patient received 1 to 10 injections (mean, 3.0 injections) for the whole course of treatment, and the total dose of bleomycin A5 was from 8 to 80 milligrams (mean, 24.0 mg). Twenty-six of 32 macrocystic lesions (81%) showed greater than 90% reduction, whereas another 6 (19%) exhibited 50% to 90% reduction. Nineteen of 30 microcystic lesions (63%) showed greater than 90% reduction; 10 (33%) had 50% to 90% reduction; and 1 (4%) had less than 50% size reduction. Of the 3 combined lesions, 2 (67%) had greater than 90% shrinkage, and 1 (3%) had less than 50% reduction. The complications included ulceration of oral mucosa, minor soft tissue atrophy, mild fever, and hematoma. There was no recurrence throughout the follow-up period. These data suggest bleomycin A5 is a safe and effective intralesional agent for the treatment of macrocystic LMs, superficial oral mucosa LM, and localized deep microcystic lesions. For extensive macrocystic LMs involving contiguous anatomic areas and diffuse microcystic lesions involving deep tissues, bleomycin A5 injection combined with resection is necessary." @default.
• W1993726573 created "2016-06-24" @default.
• W1993726573 creator A5004283796 @default.
• W1993726573 creator A5027203141 @default.
• W1993726573 creator A5034237051 @default.
• W1993726573 creator A5043007901 @default.
• W1993726573 creator A5044897833 @default.
• W1993726573 creator A5059203169 @default.
• W1993726573 creator A5073216396 @default.
• W1993726573 creator A5088831358 @default.
• W1993726573 date "2011-01-01" @default.
• W1993726573 modified "2023-10-13" @default.
• W1993726573 title "Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations" @default.
• W1993726573 cites W1964746852 @default.
• W1993726573 cites W1971732001 @default.
• W1993726573 cites W1982559817 @default.
• W1993726573 cites W1987713703 @default.
• W1993726573 cites W1987720731 @default.
• W1993726573 cites W1991792160 @default.
• W1993726573 cites W1993308107 @default.
• W1993726573 cites W1996058629 @default.
• W1993726573 cites W1999394945 @default.
• W1993726573 cites W2002197385 @default.
• W1993726573 cites W2024996743 @default.
• W1993726573 cites W2027013523 @default.
• W1993726573 cites W2038310944 @default.
• W1993726573 cites W2044262436 @default.
• W1993726573 cites W2046318554 @default.
• W1993726573 cites W2050760866 @default.
• W1993726573 cites W2057024479 @default.
• W1993726573 cites W2058122374 @default.
• W1993726573 cites W2060074319 @default.
• W1993726573 cites W2071572821 @default.
• W1993726573 cites W2093705589 @default.
• W1993726573 cites W2100288671 @default.
• W1993726573 cites W2115810991 @default.
• W1993726573 cites W2115876081 @default.
• W1993726573 cites W2127436573 @default.
• W1993726573 cites W2129181046 @default.
• W1993726573 cites W2144136228 @default.
• W1993726573 cites W2144720223 @default.
• W1993726573 cites W2397773922 @default.
• W1993726573 cites W4210956274 @default.
• W1993726573 cites W4321429293 @default.
• W1993726573 doi "https://doi.org/10.1016/j.jvs.2010.07.019" @default.
• W1993726573 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20843632" @default.
• W1993726573 hasPublicationYear "2011" @default.
• W1993726573 type Work @default.
• W1993726573 sameAs 1993726573 @default.
• W1993726573 citedByCount "62" @default.
• W1993726573 countsByYear W19937265732013 @default.
• W1993726573 countsByYear W19937265732014 @default.
• W1993726573 countsByYear W19937265732015 @default.
• W1993726573 countsByYear W19937265732016 @default.
• W1993726573 countsByYear W19937265732017 @default.
• W1993726573 countsByYear W19937265732018 @default.
• W1993726573 countsByYear W19937265732019 @default.
• W1993726573 countsByYear W19937265732020 @default.
• W1993726573 countsByYear W19937265732021 @default.
• W1993726573 countsByYear W19937265732022 @default.
• W1993726573 countsByYear W19937265732023 @default.
• W1993726573 crossrefType "journal-article" @default.
• W1993726573 hasAuthorship W1993726573A5004283796 @default.
• W1993726573 hasAuthorship W1993726573A5027203141 @default.
• W1993726573 hasAuthorship W1993726573A5034237051 @default.
• W1993726573 hasAuthorship W1993726573A5043007901 @default.
• W1993726573 hasAuthorship W1993726573A5044897833 @default.
• W1993726573 hasAuthorship W1993726573A5059203169 @default.
• W1993726573 hasAuthorship W1993726573A5073216396 @default.
• W1993726573 hasAuthorship W1993726573A5088831358 @default.
• W1993726573 hasBestOaLocation W19937265731 @default.
• W1993726573 hasConcept C141071460 @default.
• W1993726573 hasConcept C142724271 @default.
• W1993726573 hasConcept C181152851 @default.
• W1993726573 hasConcept C2776232574 @default.
• W1993726573 hasConcept C2776694085 @default.
• W1993726573 hasConcept C2778230777 @default.
• W1993726573 hasConcept C2779662492 @default.
• W1993726573 hasConcept C2781156865 @default.
• W1993726573 hasConcept C71924100 @default.
• W1993726573 hasConceptScore W1993726573C141071460 @default.
• W1993726573 hasConceptScore W1993726573C142724271 @default.
• W1993726573 hasConceptScore W1993726573C181152851 @default.
• W1993726573 hasConceptScore W1993726573C2776232574 @default.
• W1993726573 hasConceptScore W1993726573C2776694085 @default.
• W1993726573 hasConceptScore W1993726573C2778230777 @default.
• W1993726573 hasConceptScore W1993726573C2779662492 @default.
• W1993726573 hasConceptScore W1993726573C2781156865 @default.
• W1993726573 hasConceptScore W1993726573C71924100 @default.
• W1993726573 hasIssue "1" @default.
• W1993726573 hasLocation W19937265731 @default.
• W1993726573 hasLocation W19937265732 @default.
• W1993726573 hasOpenAccess W1993726573 @default.
• W1993726573 hasPrimaryLocation W19937265731 @default.
• W1993726573 hasRelatedWork W1970248395 @default.
• W1993726573 hasRelatedWork W2032705424 @default.
• W1993726573 hasRelatedWork W2064428643 @default.
• W1993726573 hasRelatedWork W2119822303 @default.

• next